We assessed the inhibitory effect of DuP 753, an or ally active angiotensin II receptor antagonist, on the pressor action of exogenous angiotensin I and II in healthy volunteers. In a single dose study, doses of 2.5, 5,10, 20, and 40 mg of DuP 753 or placebo were tested serially at one week intervals. In the multiple dose study, the administration of placebo or DuP 753 (5, 10, 20, or 40 mg, per os once daily) for eight consecutive days was evaluated. The blood pressure response to angiotensin I and II was inhibited in a dose-dependent fashion with a blocking effect still present 24 h post drug. DuP 753 also induced a dose-dependent compensatory rise in plasma renin. This new compound was well tolerated by these normal volunteers. Thus, DuP 753 appears to be a well tolerated, orally active, potent and long-lasting antagonist of angiotensin II in humans. Am J Hy pertens 1991;4:350S-354S
S aralasin (sar^ala 8 -angiotensin II) was the first receptor antagonist of angiotensin (ANG) II administered to humans. [1] [2] [3] This peptide an tagonist was not orally active and had to be ad ministered parenterally. Therefore, long-term anti hypertensive treatment was not possible. Furthermore, the antagonist was also a partial agonist. 4 Consequently, the majority of patients did not respond with a fall in blood pressure.
Furukawa and his coworkers have synthetized some imidazole derivatives that specifically block the ANG II-induced vasoconstriction. 5 Important chemical modi fications of these initial molecules have led to the syn thesis of DuP 753. 67 This compound is a potent antago nist of ANG II when administered orally to animals. 8 ' 9 We have assessed for the first time the pharmacoki netic and pharmacodynamic profile of DuP 753 after single and repeated oral administration to normal human subjects. The results suggest that DuP 753 is a potent and long-acting antagonist of ANG II not only in animals, but also in humans. 10 
METHODS
A total of 37 male subjects aged 20 to 38 years were recruited to carry out the two consecutive studies. All subjects were considered healthy on the basis of a medi cal history, a physical examination, a routine blood and urine analysis, and an electrocardiogram. The study protocols were approved by the institutional ethics committee.
In order to quantitate the pressor effect of exogenous ANG, blood pressure was measured at the finger using a photoplethysmograph (Finapres, Ohmeda, Englewood, CO). Throughout the studies, the volunteers were al lowed to continue their usual free sodium intake. They were asked to come to our research facility at 7 AM on the first day of the investigation after fasting over night. They were immediately placed in a supine posi tion and venous catheters were inserted in a vein in each forearm.
Study One (Single Dose Study) After a 30 min resting period to reach a steady baseline blood pressure and heart rate, a dose-response curve to bolus injections of ANG I was established. Angiotensin I (Senn Chemicals, Dielsdorf, Switzerland) was dissolved in 0.9% NaCl to achieve a concentration of 1 //g/mL. The bolus injec tions were started at a dose of 10 ng/kg and increased thereafter every 10 to 15 min by steps of 10 ng/kg until a systolic blood pressure increase of 25 to 40 mm Hg was reached. This test dose was then repeated at least twice. The systolic blood pressure responses to these three con secutive injections of the test dose were averaged and the resulting mean used to define the baseline response to ANG I.
DuP 753 is the potassium salt of 2-n-butyl-4-chloro-5 -hy droxymethyl -l-[(2'-4H -tetrazol -5 -yl)biphenyl -4yl)methyl] imidazole (Ε. I. du Pont de Nemours & Com pany, Wilmington, DE). 11 The dose to be administered was dissolved in 20 mL of tap water. The effect of the drug was then monitored using bolus injections of the ANG I test dose at times 15,30, and 45 min and 1, IV2,2, 2V 2 ,3,4,5,6, 7,13,23,25, and 27 (up to 33 for the 40 mg dose) h after drug intake. Between the hours 7 and 12 and again between the hours 13 and 22, the subjects were allowed to leave the clinic. This two day protocol was repeated four times in each volunteer (except for one volunteer who only had 3 administrations) and at each phase a different dose of drug or placebo was given in single-blind fashion.
Study Two (Multiple Dose Study) During the multi ple dose study, each subject received, in the mornings on 8 consecutive days, one dose of DuP 753 (either 5,10, 20, or 40 mg) or placebo. Thus, each dose or placebo was given in single-blind fashion to six subjects, with the exception of the 20 mg dose, which was taken by only five volunteers. In this second investigation, ANG II was used as the agonist. Angiotensin II (Senn Chemi cals, Dielsdorf, Switzerland) was dissolved in 0.9% NaCl to achieve a concentration of 1 //g/mL. The doseresponse curve to establish the test dose of ANG II was carried out during the week preceding the first adminis tration of DuP 753 using the same procedure described above. During study days 1 to 9, the subjects came every day at 8 AM and 8 PM to the research facility for measure ment of heart rate, weight, and blood pressure by a sphygmomanometer (sitting and standing). On study days 1 to 8, the dose of DuP 753 or placebo was admin istered at 8 AM in a similar fashion to the single-dose study. On days 1, 4, and 8, an ANG II challenge was performed before and again 6 and 12 h post-drug in take. Additional test doses were injected 24 h post drug on day 1 as well as 24, 30, and 36 h after the last dosing on day 8.
Aldosterone was determined by a direct radioimmu noassay. 12 For the measurement of plasma renin activity (PRA), generated ANG I was trapped and quantitated by high affinity antibodies. 13 ' 14 For the quantitation of immunoreactive ANG II, a new method using monoclo nal antibodies against ANG II was used. 15 Norepineph rine was measured by a radioenzymatic assay. 16 ' 17 Sub jects remained in a supine position for 30 min prior to blood sampling.
The data are provided as mean ± SEM unless other wise indicated. They were evaluated with a one way ANOVA model. A Ρ < .05 was considered significant. The correlation coefficients were calculated, when indi cated, by the method of least squares.
RESULTS
DuP 753 had no effect on resting blood pressure or pulse rate, neither after single administration nor during the 8 day treatment. The compound was well tolerated and no clinically significant side effect was observed in ei ther of the two studies. Also, blood counts, the results of routine laboratory tests and urine analysis, and electro cardiogram measurements were not modified by DuP 753.
The changes in systolic blood pressure induced by the test dose of ANG I were calculated as the difference between post-and prechallenge values for each volun teer at each dose and at each time. Compared to placebo, no clear effect was observed with the doses of 2.5 and 5 mg. Doses of 10, 20, and 40 mg induced however a dose-dependent inhibition of the response to ANG I. Figure 1 shows the dose-related inhibition of the re sponse to ANG I expressed in percent of the baseline response. The peak inhibitory effect was reached 7, 5, and 3 h after intake of the 10, 20, and 40 mg doses of DuP 753, respectively.
Compared to placebo, the 8 day treatment with DuP 753 taken once a day resulted in a dose-dependent re- (10, 20, or 40 mg) or placebo on the systolic blood pressure (SBP) response (mean ± SEM) to test doses of ANG I in healthy volunteers. Adapted from Christen et al. 10 auction in the systolic blood pressure response to ANG II throughout the treatment period. The degree of blockade achieved with the 20 and 40 mg doses was similar 6 h post-drug intake on days 1,4, and 8 (P < .01 for effect of DuP 753 ν placebo). On days 4 and 8, however, the subjects receiving 40 mg of DuP 753 showed a clear trend towards a reduced response to exogenous ANG II immediately before the morning dose of the drug (Figure 2) .
Plasma aldosterone levels fell after administration of single doses of DuP 753, but a similar decrease was also seen after placebo. The single doses of DuP 753 pro duced a dose dependent increase in plasma ANG II, while no change was observed after placebo administra tion. As early as 30 min after the highest dose of 40 mg, a small rise was already apparent. No significant change in plasma norepinephrine was observed after single ad ministration of DuP 753. Figure 3 depicts the PRA and plasma ANG II levels measured at the beginning and at the end of repeated administration of placebo or DuP 753. Both PRA and ANG II showed a marked dose-dependent increase 6 h post-drug intake, and this rise was clearly more pro nounced on day 8 than on day 1. Both variables had already increased significantly 6 h after 20 mg of DuP 753 on the first day, (P < .05 ν placebo). While the base line results on day 1 were all very similar, on day 8 there was a trend for a dose-dependent increase even of the pre-drug values. approximately 70% reduction in the systolic pressure response to ANG I or II. With this highest dose, even 24 h post-drug a definite effect was still present. Plasma renin activity and ANG II levels also responded with a dose-dependent compensatory rise as one might have expected based on earlier observations made with sara lasin, 2 as well as on the extensive experience accumu lated with angiotensin converting enzyme (ACE) inhibi tors. This compensatory rise was dose-dependent and more pronounced on day 8 of drug administration than on day 1. This also is in agreement with findings ob tained after administration of ACE inhibitors. 18 The long duration of the blocking effect of DuP 753 is also reflected in the plasma renin activity and ANG II levels. Thus, while on day 1 all predrug measurements pro vided similar results, on day 8, plasma renin activity as well as plasma ANG II were clearly increased before the administration of 20 and 40 mg as compared to the pre-drug results obtained before placebo.
DISCUSSION
No significant effect of the ANG II antagonist on plasma aldosterone could be detected. There are many possible reasons why there was no net effect of the drug on plasma aldosterone. Most importantly, the 40 mg dose did not provide maximal receptor blockade at the vascular receptors. It is also conceivable that the re peated bolus injections of ANG I or II in the face of incomplete receptor blockade may have exerted a stimu lating effect on aldosterone secretion.
The clinically most relevant question is of course how DuP 753 as a therapeutic agent compares to the various agents already available for blockade of the renin-an giotensin cascade. Obviously, the present study cannot provide any conclusive answer to this question since the drug was administered only to normal volunteers. Nev ertheless, it is already evident that this ANG II antago nist exhibits features which appear particularly promis ing as a future therapeutic agent. Compared to saralasin it has the evident and decisive advantage of being orally active. Furthermore, while the present data cannot rule out the existence of an agonistic effect of DuP 753 be cause relatively small doses were administered, it seems likely that no such effect will occur in humans, since in various animal studies none was observed at very high doses of drug. 7 These preliminary data obtained in nor mal volunteers do not allow us to predict the antihyper tensive potency and efficacy of DuP 753. Nevertheless, the findings obtained with DuP 753 in hypertensive animals and the earlier observations made with sarala sin suggest that DuP 753 will likely become an effective compound to treat hypertension and possibly conges tive heart failure. Compared to angiotensin converting enzyme inhibitors, it would have the advantage of greater specificity. It shares with the ACE inhibitors, as well as with the renin inhibitors, the unescapable fact that the closed regulatory loop of renin secretion is fully operative, and as a consequence, blockade at any point beyond the renin secreting process automatically in duces a compensatory rise in renin and ANG II. Whether this compensatory rise has any clinical conse quences remains to be seen.
